Login
TRINITY BIOTECH PLC logo

TRINITY BIOTECH PLC

trinitybiotech.com

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Financial Snapshot

Revenue
TTM
$51.36M
Gross Margin
TTM
35.26%
Net Income
TTM
-$46.17M
Current Assets
2025 Q4
$35.90M
Current Liabilities
2025 Q4
$141.2M
Current Ratio
2025 Q4
25.42%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
Book Value
2025 Q4
-$71.98M
Cash
2025 Q4
$5.138M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$17.02M

Stock Price

Loading...
Market Cap: $6.1882 Million

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support